CombinatoRx "buy," target price reduced

07/29/08 - Ladenburg Thalmann

NEW YORK, July 29 (newratings.com) - In a research note published yesterday, analysts at Ladenburg Thalmann maintain their "buy" rating on CombinatoRx (CRXX), while raising their estimates for the company. The target price has been reduced from $7.5 to $6.25.